Cardio Diagnostics Holdings, Inc. (CDIO): Total Liabilities

Annual figures by period end, from SEC filings.

$793.1K
As of 2025-12-31
$499.8K
As of 2026-06-30
-25.9%
3-year compound annual growth
$1.95M2021-12-31: $33.9K2022-12-31: $1.95M2023-12-31: $1.50M2024-12-31: $1.06M2025-12-31: $793.1K$793.1K
2021-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$793.1K-25.0%2026-03-13, Balance as of period end
2024-12-31$1.06M-29.7%2026-03-13, Balance as of period end
2023-12-31$1.50M-22.8%2025-03-20, Balance as of period end
2022-12-31$1.95Mn/m2024-04-01, Balance as of period end
2021-12-31$33.9Kn/a2023-03-31, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Cardio Diagnostics Holdings, Inc. (CDIO)2025-12-31$793.1K-25.0%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$55.82M+23.1%
Volitionrx Ltd (VNRX)2025-12-31$42.49M+19.7%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$57.22M+20.8%
Biomerica Inc (BMRA)2026-05-31$4.13M+124.4%
Anbio Biotechnology (NNNN)2025-12-31$87.8K-94.9%
Aspira Women's Health Inc. (AWHL)2025-12-31$12.39M+53.8%
Immucell Corp (ICCC)2025-12-31$15.48M-12.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$34.81M-4.3%

Compare CDIO, CLDX, VNRX, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗